Donald Gravenor

Randomized Phase II Trial of a Toll-Like Receptor 9 Agonist Oligodeoxynucleotide, PF-3512676, in Combination With First-Line Taxane Plus Platinum Chemotherapy for Advanced-Stage Non–Small-Cell Lung Cancer

Christian Manegold, Donald Gravenor, Donald Woytowitz et al. · Journal of Clinical Oncology · 2008 · 167 citations · Full text

Avelumab in patients with previously treated metastatic melanoma: phase 1b results from the JAVELIN Solid Tumor trial

Ulrich Keilholz, Janice M. Mehnert, Sebastian Bauer et al. · Journal for ImmunoTherapy of Cancer · 2019 · 82 citations · Full text

Replacement of bortezomib with carfilzomib for multiple myeloma patients progressing from bortezomib combination therapy

James R. Berenson, James Hilger, Ori Yellin et al. · Leukemia · 2014 · 76 citations · Full text

Ascorbic Acid, Hematological Malignancy, Oncology +13

Circulating tumor DNA (ctDNA) for informing adjuvant chemotherapy (ACT) in stage II/III colorectal cancer (CRC): Interim analysis of BESPOKE CRC study.

Pashtoon Murtaza Kasi, Vasily N. Aushev, Joe Ensor et al. · Journal of Clinical Oncology · 2024 · 54 citations

Surgical Oncology, Cancer Management, Adjuvant Chemotherapy +23

Phase <scp>I</scp>/<scp>II</scp> trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma

James R. Berenson, Ori Yellin, Alberto Bessudo et al. · British Journal of Haematology · 2012 · 53 citations